GLP-1s could end up being ‘the first true longevity drug’ as the world battles a rising obesity crisis
GLP-1s are the hottest drugs on the market. While doctors have prescribed these drugs to treat type-2 diabetes for decades, these treatments broke into the public consciousness when they started to be used for weight loss. U.S. approval of Novo Nordisk’s anti-obesity drug Wegovy and Eli Lilly’s Zepbound has fueled the meteoric growth of both […]
Oral GLP-1 pill shows strong weight loss and blood sugar benefits in adults with diabetes
A new oral GLP-1 medication can help adults with obesity and Type 2 diabetes lose more weight and improve their blood sugar levels compared to a placebo, according to findings from the ATTAIN-2 trial led by a UTHealth Houston researcher.
Risk of Acute Pancreatitis and Biliary Events After Initiation of Incretin-Based Medications in Patients With Type 2 Diabetes
OBJECTIVE Patients with type 2 diabetes (T2D) are at increased risk of acute pancreatitis (AP) and biliary events. Evidence remains mixed regarding the association between incretin-based therapies, such as glucagon-like peptide 1 receptor agonists (GLP-1RAs) and dipeptidyl peptidase 4 inhibitors (DPP-4is), and these outcomes. We examined the association between incretin medication use and risk of […]
Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes
OBJECTIVE To assess the effect of automated insulin delivery (AID) on glycemic and insulin outcomes in adults with insulin-treated type 2 diabetes using a glucagon-like peptide-1 receptor agonist (GLP-1 RA). RESEARCH DESIGN AND METHODS In a randomized trial comparing Control-IQ+ AID versus continuation of prestudy insulin delivery method plus continuous glucose monitoring (CGM group), 143 […]
MAHA And GLP-1s Are About To Deal A Big Blow To The Processed-Foods Industrial Complex
MAHA And GLP-1s Are About To Deal A Big Blow To The Processed-Foods Industrial Complex The US processed-food industrial complex, partly controlled by globalist mega-corps, is beginning to reckon with a new reality: Make America Healthy Again and rising weight-loss drug use are reshaping what Americans eat – and what they’re walking away from, mostly junk food loaded with toxic seed […]
Ozempic could redefine Thanksgiving across the country as users’ appetites dwindle: ‘I don’t want to hurt anyone’s feelings’
‘I will just grab the dish and not eat it,’ one GLP-1 medication user said of her favorite Thanksgiving dish
Pfizer (PFE) – Hedged Covered Call Income Campaign
Pfizer (PFE) – Hedged Covered Call Income Campaign Pfizer, Inc. BATS:PFE Wallstreet-Warriors After Pfizer’s return to price levels closer to its pre-COVID range, I personally believe the stock is undervalued relative to its current earnings profile and long-term potential. This view is also influenced by Pfizer’s recent acquisition of Metsera, which brings a pipeline of […]
New clinical trial involving more than 1,600 people with type 2 diabetes has found that a GLP-1 pill form of the drug orforglipron is similarly effective for weight loss as injectable semaglutide such as Ozempic
submitted by /u/sciencealert [link] [comments]
Study compares GLP-1 drug benefits and finds substantial variation in clinical effects
GLP-1 receptor agonists improve glycaemic control and provide renal, metabolic, and selective cardiovascular benefits in people with type 2 diabetes, based on an umbrella review of 17 meta-analyses. However, these agents consistently increase gastrointestinal adverse effects and show important distinctions between class-level outcomes and individual drug effects, particularly for semaglutide.
Alcohol Use Disorder Market to Grow Rapidly at a 13.6% CAGR by 2034 Owing to Rising Disease Prevalence, Significant Advancements in Genetically-targeted Therapies, along with Innovative Treatments such as GLP-1 Receptor Agonists | DelveInsight
The alcohol use disorder (AUD) market is set to grow due to unmet clinical needs, limited efficacy of current therapies, and rising demand for better-tolerated treatments. Expanding label indications, new regulatory approvals, increasing awareness, and reduced stigma are expected to boost…